Vertex Pharmaceuticals (VRTX) Short-Term Debt repayments (2017)

Vertex Pharmaceuticals (VRTX) recorded quarterly Short-Term Debt repayments of $300.0 million in Q1 2017.

Vertex Pharmaceuticals (VRTX) Short-Term Debt repayments (2017) Analysis & Trends

Vertex Pharmaceuticals' Short-Term Debt repayments history runs 1 years deep, the most recent figure standing at $300.0 million for Q1 2017.

In Q1 2017, Short-Term Debt repayments changed N/A year-over-year to $300.0 million; the TTM figure through Dec 2017 stood at $300.0 million (changed N/A YoY), while the FY2017 annual figure was $300.0 million, changed N/A from the prior year.
Short-Term Debt repayments was $300.0 million for Q1 2017 at Vertex Pharmaceuticals.
In the past five years, Short-Term Debt repayments ranged from a high of $300.0 million in Q1 2017 to a low of $300.0 million in Q1 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Short-Term Debt repayments (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	102,000.00
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-482,347.21
10	Regeneron Pharmaceuticals	63.43 Bn	54.67 Bn	3.31 Bn	-

Download Data

Date	Value
Mar 31, 2017	300.00 Mn
Mar 31, 2017	300.00 Mn